HCW Biologics (HCWB) Profit After Tax (2020 - 2026)

HCW Biologics (HCWB) has reported Profit After Tax for 7 consecutive years, with -$5.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 170.74% year-over-year to -$5.2 million; the trailing twelve-month figure through Jun 2026 stood at -$11.0 million (up 3.67% YoY), and the FY2025 full-year result was -$8.0 million, up 73.49% from the prior year.
• Profit After Tax fell to -$5.2 million in Q2 2026 per HCWB's latest filing, from $719232.0 in the prior quarter.
• Across five years, Profit After Tax topped out at $719232.0 in Q4 2025 and bottomed at -$15.3 million in Q2 2024.
• Historically, Profit After Tax has averaged -$4.9 million across 5 years, with a median of -$4.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax tumbled 254.99% in 2024, then soared 121.32% in 2025.
• Over 5 years, Profit After Tax stood at -$5.4 million in 2022, then plunged by 97.1% to -$10.7 million in 2023, then surged by 68.42% to -$3.4 million in 2024, then soared by 121.32% to $719232.0 in 2025, then tumbled by 825.67% to -$5.2 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$5.2 million, $719232.0, and -$4.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.